Katsumaro Kubo1, Koichi Wadasaki2, Katsunori Shinozaki3. 1. Department of Radiation Oncology, Hiroshima Prefectural Hospital, 1-5-54 Ujinakanda Minami-ku Hiroshima-shi, Hiroshima, 734-0004, Japan. maro1987@hotmail.co.jp. 2. Department of Radiation Oncology, Hiroshima Prefectural Hospital, 1-5-54 Ujinakanda Minami-ku Hiroshima-shi, Hiroshima, 734-0004, Japan. 3. Department of Clinical Oncology, Hiroshima Prefectural Hospital, 1-5-54 Ujinakanda Minami-ku Hiroshima-shi, Hiroshima, 734-0004, Japan.
Abstract
PURPOSE: To identify predictive factors for local control of locally advanced esophageal cancer by chemoradiotherapy, the relationship between clinical features, including macroscopic tumor type, and treatment outcome was analyzed in 83 patients. MATERIALS AND METHODS: Macroscopic tumor type was defined by endoscopy as follows: type 1: protruding type; type 2: ulcerative and localized type; type 3: ulcerative and infiltrative type; type 4: diffusely infiltrative type; and type 5: unclassifiable type. We analyzed the overall survival, cause-specific survival, local progression-free rate, and predictive factors for locally advanced esophageal cancer after chemoradiotherapy. RESULTS: The median follow-up period at the time of evaluation was 59 months among survivors. The 5-year overall survival, cause-specific survival, and local progression-free rates for type 1 and other types were 37.0% and 23.3% (P = 0.4255), 71.8% and 30.3% (P = 0.0325), and 100% and 63.3% (P = 0.0246), respectively. Macroscopic tumor type (type 1) was the most significant predictive factor of cause-specific survival and local progression-free rates. CONCLUSIONS: Macroscopic tumor type 1 was the significant favorable predictive factor for local control. The study results suggested that the macroscopic tumor type was useful in predicting tumor responses.
PURPOSE: To identify predictive factors for local control of locally advanced esophageal cancer by chemoradiotherapy, the relationship between clinical features, including macroscopic tumor type, and treatment outcome was analyzed in 83 patients. MATERIALS AND METHODS: Macroscopic tumor type was defined by endoscopy as follows: type 1: protruding type; type 2: ulcerative and localized type; type 3: ulcerative and infiltrative type; type 4: diffusely infiltrative type; and type 5: unclassifiable type. We analyzed the overall survival, cause-specific survival, local progression-free rate, and predictive factors for locally advanced esophageal cancer after chemoradiotherapy. RESULTS: The median follow-up period at the time of evaluation was 59 months among survivors. The 5-year overall survival, cause-specific survival, and local progression-free rates for type 1 and other types were 37.0% and 23.3% (P = 0.4255), 71.8% and 30.3% (P = 0.0325), and 100% and 63.3% (P = 0.0246), respectively. Macroscopic tumor type (type 1) was the most significant predictive factor of cause-specific survival and local progression-free rates. CONCLUSIONS: Macroscopic tumor type 1 was the significant favorable predictive factor for local control. The study results suggested that the macroscopic tumor type was useful in predicting tumor responses.
Entities:
Keywords:
Chemoradiotherapy; Endoscopy; Esophageal cancer
Authors: M Murakami; Y Kuroda; T Nakajima; Y Okamoto; T Mizowaki; F Kusumi; K Hajiro; S Nishimura; S Matsusue; H Takeda Journal: Int J Radiat Oncol Biol Phys Date: 1999-09-01 Impact factor: 7.038
Authors: Arya Amini; Jaffer Ajani; Ritsuko Komaki; Pamela K Allen; Bruce D Minsky; Mariela Blum; Lianchun Xiao; Akihiro Suzuki; Wayne Hofstetter; Stephen Swisher; Daniel Gomez; Zhongxing Liao; Jeffrey H Lee; Manoop S Bhutani; James W Welsh Journal: Ann Surg Oncol Date: 2013-11-07 Impact factor: 5.344
Authors: E Versteijne; H W M van Laarhoven; J E van Hooft; R M van Os; E D Geijsen; M I van Berge Henegouwen; M C C M Hulshof Journal: Dis Esophagus Date: 2014-04-11 Impact factor: 3.429
Authors: A Ohtsu; N Boku; K Muro; K Chin; M Muto; S Yoshida; M Satake; S Ishikura; T Ogino; Y Miyata; S Seki; K Kaneko; A Nakamura Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544